Ethynylandrostanediol

A synthetic anabolic-androgenic steroid

Ethynylandrostanediol is a synthetic anabolic-androgenic steroid (AAS) that was developed in the mid-20th century. It is a derivative of androstanediol, a naturally occurring androgen and anabolic steroid.

Chemical Structure

Ethynylandrostanediol is chemically known as 17α-ethynyl-5α-androstane-3β,17β-diol. It is a modified form of androstanediol, with an ethynyl group at the 17α position. This modification is intended to enhance the compound's oral bioavailability and resistance to metabolic degradation.

Pharmacology

As an anabolic-androgenic steroid, ethynylandrostanediol exhibits both androgenic and anabolic properties. It binds to androgen receptors in various tissues, promoting protein synthesis and muscle growth. The ethynyl group at the 17α position helps to prevent rapid metabolism by the liver, allowing the compound to be effective when administered orally.

Medical Uses

Ethynylandrostanediol was initially developed for potential use in hormone replacement therapy and the treatment of conditions associated with low androgen levels. However, like many other synthetic AAS, its use in clinical practice has been limited due to concerns about side effects and the availability of safer alternatives.

Side Effects

The use of ethynylandrostanediol, like other anabolic steroids, can lead to a range of side effects. These may include:

• Virilization in women, such as deepening of the voice and increased body hair.
• Liver toxicity, due to the 17α-alkylated structure.
• Cardiovascular issues, such as hypertension and alterations in lipid profiles.
• Endocrine disruption, including suppression of natural testosterone production.

Legal Status

Ethynylandrostanediol, like many other anabolic steroids, is classified as a controlled substance in many countries. Its use is restricted to specific medical conditions and is often subject to strict regulations.

Related Compounds

Ethynylandrostanediol is related to other synthetic anabolic steroids such as methandrostenolone and stanozolol. These compounds share similar anabolic and androgenic properties but differ in their chemical structures and pharmacokinetics.

Related Pages

• Anabolic steroid
• Androgen
• Hormone replacement therapy
• Virilization
• Liver toxicity